Project Details
| Short title | HLX14-002-PMOP301 |
|---|---|
| Acronym | HLX14-002-PMOP301 |
| Status | Active |
| Effective start/end date | 18/07/22 → 17/07/27 |
CTU: Randomized, Double-Blind, International Multicenter, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women with Osteoporosis at High Risk of Fracture
- Preda, Veronica (Primary Chief Investigator)
- Chester, Catherine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research